07
2020-05
Ten years of consistent effort finally bear fruit
In 2008, after nearly 20 years studying and working in the US, Dr. Youzhi Tong made a momentous decision to return to China and start a new drug discovery company. “People who choose to start a busine
16
2020-04
Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement
Suzhou Kintor Pharmaceutical ,Inc. ("Kintor Pharmaceutical ")and Sinopharm Holding Co., Ltd. signed the strategic cooperation agreement on the innovation of topical drug Pyrilutamide (KX-826) in Shanghai. Both sides carry out all-round cooperation on patient-centered product design, future business channel development and terminal services, so as to prepare for future market development and better service for patients.
28
2020-02
To further strengthen the support and speed up the cultivation of a group of leading biopharmaceutical enterprises with global influence, the Party Working Committee and Management Committee of the park carried out a comprehensive and detailed sorting of biopharmaceutical enterprises in the park and selected a group of leading enterprises with independent brands.
17
2020-02
Suzhou Kintor Obtained Approval to Conduct Clinical Trials for SMO Antagonists in China
On February 17, 2020, National Medical Products Administration officially granted the clinical trials notification to Suzhou Kintor Pharmaceuticals, Inc.(hereinafter referred to as “Suzhou Kintor") and agreed to approve clinical trials to be conducted on the SMO antagonist, GT1708F.
20
2019-12
On December 20, 2019, Future Top 100 Medical Enterprises Meeting of 2019 under the theme of “New Life Increment” was kicked off in Beijing· Jiuhua Villa. The meeting focused on multiple factors such as policy environment, technology environment and demanding spaces, provided comprehensive interpretation of the future development trend of health care industry to promote the reform of innovative health care industry.
13
2019-12
Ms. Lu Yan Serves as Kintor's Chief Financial Officer
[Suzhou, December 13, 2019] 真人直营投注网站 and its subsidiaries (the "Group") officially announced the appointment of Ms. Lu Yan as Chief Financial Officer who would be responsible for our capital market strategy, financial planning, investor relations and internal controls
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn